Literature DB >> 15120100

Explosive-aggressive behavior related to bilateral subthalamic stimulation.

M Sensi1, R Eleopra, M A Cavallo, E Sette, P Milani, R Quatrale, J G Capone, V Tugnoli, M R Tola, E Granieri, P G Data.   

Abstract

We describe a patient with Parkinson's Disease who underwent bilateral subthalamic nucleus deep brain stimulation and later presented with episodes of aggressive behavior disorder with disturbed impulse control and an inability to control anger likely related to the deep brain stimulation "switch-on stimulation". We hypothesize that increasing voltage intensity could influence neighboring passing fibers coming from basal limbic system that are involved in the regulation of affect and emotional behavior. We suggest investigating these neuropsychological disturbances considering their influence on quality of life after surgery.

Entities:  

Mesh：

Year:  2004        PMID： 15120100     DOI： 10.1016/j.parkreldis.2004.01.007

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN： 1353-8020            Impact factor:   4.891


  20 in total

1.  Influence of bilateral Stn-stimulation on psychiatric symptoms and psychosocial functioning in patients with Parkinson's disease.

Authors:  K Kalteis; H Standhardt; I Kryspin-Exner; T Brücke; D Volc; F Alesch
Journal:  J Neural Transm (Vienna)       Date:  2005-12-16       Impact factor: 3.575

Review 2.  New pharmacological and neuromodulation approaches for impulsive-compulsive behaviors in Parkinson's disease.

Authors:  Giacomo Grassi; Giovanni Albani; Federica Terenzi; Lorenzo Razzolini; Silvia Ramat
Journal:  Neurol Sci       Date:  2021-04-14       Impact factor: 3.307

3.  The ethics of deep brain stimulation (DBS).

Authors:  Marcus Unterrainer; Fuat S Oduncu
Journal:  Med Health Care Philos       Date:  2015-11

4.  Do patient's get angrier following STN, GPi, and thalamic deep brain stimulation.

Authors:  Adam P Burdick; Kelly D Foote; Samuel Wu; Dawn Bowers; Pam Zeilman; Charles E Jacobson; Herbert E Ward; Michael S Okun
Journal:  Neuroimage       Date:  2010-10-04       Impact factor: 6.556

Review 5.  Management of impulse control disorders in Parkinson's disease: Controversies and future approaches.

Authors:  Michael Samuel; Maria Rodriguez-Oroz; Angelo Antonini; Jonathan M Brotchie; Kallol Ray Chaudhuri; Richard G Brown; Wendy R Galpern; Melissa J Nirenberg; Michael S Okun; Anthony E Lang
Journal:  Mov Disord       Date:  2015-01-21       Impact factor: 10.338

Review 6.  The Subthalamic Nucleus, Limbic Function, and Impulse Control.

Authors:  P Justin Rossi; Aysegul Gunduz; Michael S Okun
Journal:  Neuropsychol Rev       Date:  2015-11-14       Impact factor: 7.444

7.  Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial.

Authors:  Michael S Okun; Hubert H Fernandez; Samuel S Wu; Lindsey Kirsch-Darrow; Dawn Bowers; Frank Bova; Michele Suelter; Charles E Jacobson; Xinping Wang; Clifford W Gordon; Pam Zeilman; Janet Romrell; Pam Martin; Herbert Ward; Ramon L Rodriguez; Kelly D Foote
Journal:  Ann Neurol       Date:  2009-05       Impact factor: 10.422

8.  Stimulation-Induced Transient Nonmotor Psychiatric Symptoms following Subthalamic Deep Brain Stimulation in Patients with Parkinson's Disease: Association with Clinical Outcomes and Neuroanatomical Correlates.

Authors:  Osama A Abulseoud; Aimen Kasasbeh; Hoon-Ki Min; Julie A Fields; Susannah J Tye; Stephan Goerss; Emily J Knight; Shirlene M Sampson; Bryan T Klassen; Joseph Y Matsumoto; Cynthia Stoppel; Kendall H Lee; Mark A Frye
Journal:  Stereotact Funct Neurosurg       Date:  2016-04-20       Impact factor: 1.875

9.  Impulse control disorders following deep brain stimulation of the subthalamic nucleus in Parkinson's disease: clinical aspects.

Authors:  Polyvios Demetriades; Hugh Rickards; Andrea Eugenio Cavanna
Journal:  Parkinsons Dis       Date:  2011-02-20

Review 10.  Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Authors:  Dag Nyholm
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 5.577
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.